Lazard Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Lazard Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18,440	Closed	-$70K	–	1841
2020 Q1	$70K	Buy	+18,440	New	+$79.4K	﹤0.01%	1082

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Lazard Asset Management's PGNX Position: Q2 2020 in Review

Lazard Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 18,440 shares — an estimated $70K sold.

Lazard Asset Management first reported a position in PGNX in Q1 2020 and held it in 1 quarter. The position peaked at $70K in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Lazard Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Lazard Asset Management sold 18,440 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $70K.
Lazard Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2020 and held it in 1 quarter.
Lazard Asset Management's Progenics Pharmaceuticals Inc position peaked at $70K in Q1 2020.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Lazard Asset Management's 13F filing for Q2 2020, filed 13 Aug 2020.